Beijing, China · Founded 2016 · Privately Held (backing)
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. CHIGENOVO is based in Beijing, China and was founded in 2016. Its last reported valuation was $110 million in Mar 2022. It has raised $41 million.
Last reported valuation
$110.4M
Oct 2026
Priced at
—
Total raised
$41.0M
Last round
—
Team — not yet on record
No current team members for CHIGENOVO are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of CHIGENOVO with a free account
·Watch CHIGENOVO: the Monday email on marks, rounds and moves
